history of glp-1 drugs The evolution weight loss drugs: from dangers to blockbusters | BioKnow posted on the topic GLP-1 Agonists: A Comprehensive Overview

Especially at concentrations of 10100 nM Liraglutide lead to a significant reduction in proliferation and DNA synthesis as observed in cell counting, MTS, 3-(4,5-di methylthiazol-2-yl) 2,5-diphenyltetrazolium bromide (MTT) and [H]-thymidine incorporation assays [13, 20]

[DOI] [PubMed] [Google Scholar] 104.Wiviott S.D., Raz I., Bonaca M.P., Mosenzon O., Kato E.T., Cahn A., Silverman M.G., Zelniker T.A., Kuder J.F., Murphy S.A., et al

Overview of current and emerging GLP-1 receptor agonists

[DOI] [PMC free article] [PubMed] [Google Scholar] 43.de Jager J., Kooy A., Lehert P., Wulffele M.G., van der Kolk J., Bets D., Verburg J., Donker A.J., Stehouwer C.D

Allulose and GLP-1 Secretion: What In Vitro and Animal Studies Reveal In vitro and rodent studies suggest allulose may trigger GLP-1 secretion from intestinal L-cells more robustly than glucose, possibly by modulating sweet taste receptors (TAS1R2/TAS1R3) or metabolic sensors

The first was a multi-center study that used data from 33,021 participants and found that GLP-1/GIP agonist and SGLT2 inhibitor use were associated with comparable rates of new retinopathy development and worsening of existing nonproliferative retinopathy